The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure.

Date publication

mai 2016

Journal

Expert opinion on drug safety

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Pitt B, Rossignol P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26958701

Résumé

Mineralocorticoid receptor antagonists (MRAs) have been accorded a class 1 indication for patients with chronic heart failure and a reduced left ventricular ejection fraction (HFREF) in both European and American guidelines. Uptake, however, has been less than optimal largely due to concerns about their safety, in particular the risk of hyperkalemia and renal dysfunction.

Mots clés

Heart Failure, drug therapy, Hospitalization, Humans, Hyperkalemia, chemically induced, Kidney Diseases, chemically induced, Mineralocorticoid Receptor Antagonists, adverse effects, Patient Selection, Practice Guidelines as Topic, Ventricular Dysfunction, Left, drug therapy

Référence

Expert Opin Drug Saf. 2016 May;15(5):659-65